Jefferies, BofA Securities and Cantor are acting as joint book-running managers for the offering. LifeSci Capital and Oppenheimer & Co. are acting as co-lead managers for the offering. H.C. Wainwright ...
About BioSyent Inc. Listed on the TSX Venture Exchange under the trading symbol “RX”, BioSyent is a profitable growth-oriented specialty pharmaceutical company focused on in-licensing or acquiring ...
Dr John Levine, Chair of the BMT CTN Steering Committee and Professor of Internal Medicine and Pediatrics, Icahn School of Medicine at Mount Sinai, New York said: “We are delighted to be partnering ...
Ruiz, MD, FASRS, as Chair of the Scientific Advisory Board, bring invaluable clinical development expertise to VIS-101 Program The ability to attract seasoned ophthalmology leaders highlights the ...
Seren Advanced Dentistry Oxnard today formally announced the introduction of biomimetic conservative dentistry as part of its restorative care offerings. The announcement marks a structured update to ...
IRVING, Texas, Nov. 20, 2025 (GLOBE NEWSWIRE) -- CHRISTUS Health has been recognized as a national 2025 “Most Wired” health provider for digital transformation that influences quality and ...
As of September 30, 2025, the Company had $48.6 million of outstanding indebtedness with a weighted-average annual interest rate of 5.0% and a weighted-average maturity of approximately 16 years. For ...
MISSISSAUGA, Ontario, Nov. 20, 2025 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today its financial results for the three months (Q3) and nine months (YTD) ended September ...
As an “off-the-shelf” therapy, MiNK-215 can be manufactured at scale and delivered on demand—offering a new therapeutic strategy for patients with solid tumors that have long been unresponsive to ...
MedX Holdings, Inc. (OTC: MEDH) LazyDaze Posts Strong Q3 Momentum and Reinforces Its Foundation Ahead of 2026 Expansion Disciplined growth, strengthened operations, and a cannabis model built for real ...
-- Favorable Safety Profile: PAS-004 has been well-tolerated with all treatment-related adverse events Grade 1 or 2, no ocular or cardio toxicity, and limited rash, nausea, diarrhea, and vomiting to ...
RxSight’s management is scheduled to present on Wednesday, December 3, 2025, at 12:00 p.m. Eastern Time. A live and archived webcast of the presentation will be available at: https://investors.rxsight ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback